Facing Humira cliff, AbbVie sees return to ‘strong growth’ by 2025

Weeks before Humira loses U.S. patent exclusivity, AbbVie’s Rick Gonzalez laid out the company’s expectations for the coming years, including a return to growth in 2025 and an immunology franchise whose top two drugs could surpass Humira’s peak annual revenues later in the decade.

Although AbbVie Inc. (NYSE:ABBV) won’t issue sales guidance for 2023 until its next earnings call, the company expects revenues from top seller Humira adalimumab to decline as biosimilar competition enters the picture. Amgen Inc. (NASDAQ:AMGN) is anticipating its launch of Amjevita adalimumab-atto on Jan. 31, and more biosimilars are set to enter the market later this year...